X

Medicamen Biotech Ltd. Stock Analysis

Small Cap
Evaluated by 223 users | BSE: 531146 | NSE: |
Pharmaceuticals & Drugs
Medicamen Biotech Limited was incorporated in December 1993, it is a widely held, Globaly Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. Medicamen Biotech Limited is committed to produce and provide...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 11.37%2.19%-7.39%8.51%7.76%6.91%18.19%16.37%12.02%10.27%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 1231016473.377.867.382.5112123117
Y-o-Y Gr. Rt.--18.3%-36.3%14.5%6.2%-13.5%22.6%35.2%10%-4.3%
Adjusted EPS (Rs.) 2.37-1.34-6-0.1-0.040.14.757.728.819.23
Y-o-Y Gr. Rt.--156.5%NANANANA4650%62.5%14.1%4.8%
Book Value per Share (Rs.) 25.0723.9318.5118.2617.7717.9224.7363.6873.6998.58
Adjusted Net Profit 1.9-1.1-5.1-0.100.15910.311.3
Net Op. Cash Flow (Rs. Cr.) 11.4-3.5-1.65.1-3.36.23.6-5.54.311.7
Debt to Cash Flow from Ops 0.86-3.92-10.743-6.333.34.9-2.662.730.98
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Medicamen Biotech Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -0.5%8.6%12.5%-4.3%
Adjusted EPS 16.3%NA24.8%4.8%
Book Value per Share 16.440.958.633.8
Share Price 36% 62.4% -12.1% -1.6%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 10.2-5.44-28.44-0.53-0.220.5622.3717.8112.7810.79
Operating Profit Margin (%) 5.162.68-0.47.146.528.2214.0515.0614.2515.5
Net Profit Margin (%) 1.52-1.1-7.96-0.12-0.050.156.068.18.49.61
Debt to Equity 0.50.691.080.951.231.140.680.190.140.1
Working Capital Days 115153233198201230197196235287
Cash Conversion Cycle 20155238424237647471
Entity Percentage Holding
Promoters 44.77%
Institutions 0.47%
Non-Institutions 54.76%
Pledged *31.290.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Medicamen Biotech's performance infers:

Medicamen Biotech earnings have grown by 0%, whereas share price has appreciated 62.4% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Medicamen Biotech share prices over the last 10 years. Here is what we found out:

Medicamen Biotech share price has appreciated 30.4% annually over the past ten years.

Medicamen Biotech Limited was incorporated in December 1993, it is a widely held, Globaly Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. Medicamen Biotech Limited is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical fraternity since inception.

Medicamen Biotech

Medicamen Biotech Limited was incorporated in December 1993, it is a widely held, Globaly Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. Medicamen Biotech Limited is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical fraternity since inception.

Medicamen Biotech started its operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted Mr. B.K. Gupta - Managing Director of the company to go for own manufacturing facilities. Thus in the later part of 1994 a land of 2,10,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured.

In 1995 Medicamen Biotech Limited was enlisted in Bombay Stock Exchange and public issue was oversubscribed by more than 11 times. Within a span of 10 years Medicamen Biotech Limited is now among top 50 Indian export company.

In the year 2005 keeping the pace with the ever increasing demand and fulfilling the commitment, a second unit was installed in the Tax free zone at Haridwar in the state of Uttarakhand .The Unit II is fully operational from April 2007 with ultra modern manufacturing facilities.

Product range of the company includes:

The company is the Manufacturer and supplier of Comprehensive range of products:

  • Tablets
  • Capsules
  • Liquid Syrup
  • Dry Syrup (Beta Lactum and Non Beta Lactum)
  • Ointment
  • ORS

Achievements/ recognition:

The company is the receipents of the following certificates & awards:

  • WHO-GMP
  • ISO 9001: 2000
  • Star Export House
  • Certificate Of Merit
  • “Niryat Shree” for the four consecutive years from 2002 to 2005 from Government of India
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback